ReviewJournal of clinical medicine2025
Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Metabolic profiling of healthy vs. syndrome-associated obesity and effects of six-month metformin therapy.Acta diabetologica · 2026 · on this mapTrial
- Sarcopenia in Indian Males Having Clinically Significant Liver Fibrosis in Type 2 Diabetes: A Tertiary-Centre Cross-Sectional Study to Estimate the Prevalence and Associated Factors.Journal of frailty, sarcopenia and falls · 2026Article
- Comparative efficacy of various exercise therapies for metabolic syndrome a systematic review and network meta-analysis.iScience · 2026Article
- Metformin-phytochemical combination therapy in metabolic dysfunction-associated steatotic liver disease: mechanistic insights and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Association between metabolic signatures of predicted VAT mass and risk of MASLD and other chronic liver diseases.International journal of obesity (2005) · 2026Article
- Integrated serum metabolomics and MRI biomarkers for MASLD: a practical framework for noninvasive staging and monitoring.Abdominal radiology (New York) · 2026Review
- Amino Acids-Potential Biomarkers of Histological Features for MASLD in Pediatric Obesity.International journal of molecular sciences · 2026Review
- Effects of Kochia scoparia seed infusion on calorie-rich diet-induced metabolic dysfunction and histopathological alterations in liver, adipose tissue and coronaries in rats.Journal of molecular histology · 2026Article
- A Retrospective Analysis of Hepatic Disease Burden and Progression in a Hospital-Based Romanian Cohort Using Integrated Cross-Sectional and Longitudinal Data (2019-2023).Journal of clinical medicine · 2026Article
- Metabolic-associated steatotic liver disease in children and adolescents: a scoping review and narrative synthesis of epidemiology, risk factors, and screening approaches with emerging implications for sub-Saharan Africa.Frontiers in endocrinology · 2026Article
- Exploring the multifaceted roles of beta-defensins in prediabetes: a detailed review.Frontiers in endocrinology · 2026Review
- Article
- Anthocyanins Modulation of Gut Microbiota to Reverse Obesity-Driven Inflammation and Insulin Resistance.Nutrients · 2025Review
- Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum.Current obesity reports · 2025Review
- Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), encompasses a spectrum of liver diseases characterized by hepatic steatosis, the presence of at least one cardiometabolic risk factor, and no other apparent cause. Metabolic syndrome (MetS) is a cluster of clinical conditions associated with increased risk of cardiovascular disease, type 2 diabetes, and overall morbidity and mortality. This narrative review summarizes the changes in the management of people with MetS and NAFLD/MASLD from screening to therapeutic strategies that have occurred in the last decades. Specifically, we underline the clinical importance of considering the different impacts of simple steatosis and advanced fibrosis and provide an up-to-date overview on non-invasive diagnostic tests (i.e., imaging and serum biomarkers), which now offer acceptable accuracy and are globally more accessible. Early detection of MetS and MASLD is a top priority as it allows for timely interventions, primarily through lifestyle modification. The liver and cardiovascular benefits of a global and multidimensional approach are not negligible. Therefore, a holistic approach to both conditions, MetS and related chronic liver disease, should be applied to improve overall health and longevity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.